Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press10110.17650/1726-9776-2013-9-2-73-77REVIEWОБЗОРCURRENT POSSIBILITIES OF DRUG THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCERСОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ЛЕКАРСТВЕННОГО ЛЕЧЕНИЯ КАСТРАЦИОННО-РЕЗИСТЕНТНОГО РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫMarkovaA. S.МарковаА. С.
Russian Federation
mark-an@yandex.ruN.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва300620139273772707201427072014https://oncourology.abvpress.ru/oncur/article/view/101

The advent of a variety of new drugs to treat castration-resistant prostate cancer (CRPC), which have demonstrated their efficacy in increasing overall and progression-free survival, has considerably enhanced treatment possibilities in this category of patients. The standard treatment of metastatic CRPC (mCRPC) remains to be first-line chemotherapy with docetaxel 75 mg/m2 in combination with prednisolone 10 mg/day every 3 weeks. The new drugs also available in Russia are cabazitaxel and abiraterone acetate, which are approved for second-line treatment in mCRPC patients treated with docetaxel. The optimum sequence of therapy and the time of its use in view of the heterogeneity of a CRPC patient population remain open.

Появление целого ряда новых препаратов для лечения кастрационно-резистентного рака предстательной железы (КРРПЖ), доказавших свою эффективность в отношении увеличения общей и беспрогрессивной выживаемости, значительно расширило возможности лечения этой категории пациентов. Стандартом лечения метастатического КРРПЖ (мКРРПЖ) в 1-й линии остается химиотерапия доцетакселом в дозировке 75 мг/м2 в сочетании с преднизолоном в дозе 10 мг/сут курсом каждые 3 нед. Новыми препаратами, доступными в том числе и в России, являются кабазитаксел и абиратерона ацетат, одобренные для применения во 2-й линии у пациентов с мКРРПЖ, получавших доцетаксел. Остается открытым вопрос об оптимальной последовательности терапии и сроках ее назначения с учетом гетерогенности популяции больных КРРПЖ.

castration-resistant prostate cancerdocetaxelcabazitaxelabiraterone acetateкастрационно-резистентный рак предстательной железыдоцетакселкабазитакселабиратерона ацетат1. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России. 2013. 289 с.Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России. 2013. 289 с.2. GLOBOCAN, 2008. http://globocan.iarc.fr/3. Состояние онкологической помощи населению России в 2011 году. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петрово й. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздравсоцразвития России, 2012. 240 с.GLOBOCAN, 2008. http://globocan.iarc.fr/3. Состояние онкологической помощи населению России в 2011 году. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петрово й. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздравсоцразвития России, 2012. 240 с.4. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–7.Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–7.5. Shelley M., Harrison C., Coles B. et al. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database of Syst Rev 2006;18(4):CD005247.Shelley M., Harrison C., Coles B. et al. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database of Syst Rev 2006;18(4):CD005247.6. Crawford E.D., Eisenberger M.A., McLoed D.G. et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419–24.Crawford E.D., Eisenberger M.A., McLoed D.G. et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419–24.7. Dijkman G.A., Janknegt R.A., De Reijke T.H.M. et al. Long-term efficacy and safety of nilutamide plus castration in advanced stage prostate cancer, and the significance of early prostate specific antigen normalization. J Urol 1997;158:160–3.Dijkman G.A., Janknegt R.A., De Reijke T.H.M. et al. Long-term efficacy and safety of nilutamide plus castration in advanced stage prostate cancer, and the significance of early prostate specific antigen normalization. J Urol 1997;158:160–3.8. Eisenberger M.A., Blumenstein B.A., Crawford E.D. et al. Bilateral orchiec tomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036–42.Eisenberger M.A., Blumenstein B.A., Crawford E.D. et al. Bilateral orchiec tomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036–42.9. Heidenreich A., Bastian P.J., Bellmunt J. et al. EAU Guidelines on Prostate Cancer. European Association of Urology Guidelines, 2013. P. 1–154.Heidenreich A., Bastian P.J., Bellmunt J. et al. EAU Guidelines on Prostate Cancer. European Association of Urology Guidelines, 2013. P. 1–154.10. Kirby M., Hirst C., Crawford E.D. Characterising the castration-resistant prostate cancer population: a systematic review». Int J Clin Pract 2011;65(11):1180–92.Kirby M., Hirst C., Crawford E.D. Characterising the castration-resistant prostate cancer population: a systematic review». Int J Clin Pract 2011;65(11):1180–92.11. Locke J.A., Guns E.S., Lubik A.A. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407–15.Locke J.A., Guns E.S., Lubik A.A. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407–15.12. Halkidou K., Gnanapragasam V.J., Meht a P.B. et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003;22(16):2466–77.Halkidou K., Gnanapragasam V.J., Meht a P.B. et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003;22(16):2466–77.13. Grossmann M.E., Huang H., Tindall D.J. Androgen receptor signaling in androgenrefractory prostate cancer. J Natl Cancer Inst 2001;21;93(22):1687–97.Grossmann M.E., Huang H., Tindall D.J. Androgen receptor signaling in androgenrefractory prostate cancer. J Natl Cancer Inst 2001;21;93(22):1687–97.14. Halabi S., Small E., Kantoff P. et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232–7.Halabi S., Small E., Kantoff P. et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232–7.15. Petrylak D.P., Tangen C.M., Hussain M.H.A. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.Petrylak D.P., Tangen C.M., Hussain M.H.A. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.16. Tannock I.A., de Wit R., Berry W.R. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med 2004;351:1502–12.Tannock I.A., de Wit R., Berry W.R. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med 2004;351:1502–12.17. Kantoff P.W., Halabi S., Conaway M. et al. Hydrocortisone with or without mitoxantrone in men with hormonerefractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17(8):2506–13.Kantoff P.W., Halabi S., Conaway M. et al. Hydrocortisone with or without mitoxantrone in men with hormonerefractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17(8):2506–13.18. Tannock I.F., Osoba D., Stockler D.R. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756–64.Tannock I.F., Osoba D., Stockler D.R. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756–64.19. de Bono J., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376: 1147–54.de Bono J., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376: 1147–54.20. Rehman Y., Rosenberg J.E. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Design Dev Ther 2012;6:13–8.Rehman Y., Rosenberg J.E. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Design Dev Ther 2012;6:13–8.21. Danila D.C., Morris M.J., de Bono J.S. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel treated castration-resistant prostate cancer. J ClinOncol 2010;28:1496–501.Danila D.C., Morris M.J., de Bono J.S. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel treated castration-resistant prostate cancer. J ClinOncol 2010;28:1496–501.22. de Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.de Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.23. O'Donnell A., Judson I., Dowsett M. et al. Hormonal impact of the 17 alphahydroxylase/ C17, 20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317–25.O'Donnell A., Judson I., Dowsett M. et al. Hormonal impact of the 17 alphahydroxylase/ C17, 20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317–25.24. Danila D., Heller G., Gignac G. et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;(13):7053–8.Danila D., Heller G., Gignac G. et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;(13):7053–8.25. Eisenberger M.A., Garret-Mayer E.S., Ou Yang Y. et al. Multivariate prognostic nomogram incorporation PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC). Abstract ASCO. J Clin Oncol 2007;25 (18S):5058.Eisenberger M.A., Garret-Mayer E.S., Ou Yang Y. et al. Multivariate prognostic nomogram incorporation PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC). Abstract ASCO. J Clin Oncol 2007;25 (18S):5058.26. Azria D., Massard C., Tosi D. et al. An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response. J Clin Oncol 2012;30 (suppl 5; abstr 149).Azria D., Massard C., Tosi D. et al. An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response. J Clin Oncol 2012;30 (suppl 5; abstr 149).27. De Bono J.S., Oudard S., Ozguroglu M. et al. A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011;29: (suppl; abstr 4526).De Bono J.S., Oudard S., Ozguroglu M. et al. A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011;29: (suppl; abstr 4526).28. Loriot Y., Massard C., Albiges L. et al. Personalizing treatment in patients with castrateresistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity. J ClinOncol 2012;30 (suppl 5; abstr 213).Loriot Y., Massard C., Albiges L. et al. Personalizing treatment in patients with castrateresistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity. J ClinOncol 2012;30 (suppl 5; abstr 213).29. Saad F., Shore N.D., Van Poppel H. et al. Abiraterone acetate in metastatic castrationresistant prostate cancer patients without prior chemotherapy – interim analysis of the COUAA-302 phase 3 trial. J Urolvol 2013;189, abstr. 713.Saad F., Shore N.D., Van Poppel H. et al. Abiraterone acetate in metastatic castrationresistant prostate cancer patients without prior chemotherapy – interim analysis of the COUAA-302 phase 3 trial. J Urolvol 2013;189, abstr. 713.